Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VDd Combination in Newly Diagnosed Multiple Myeloma
NCT00116961Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jun 2005
- Primary completion
- Jan 2007
- Modality
- DNA Intercalators/Alkylators, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and doxorubicin in multiple myeloma (MM), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Complete Response and Near Complete Response Rate. Started Jun 2005; status: completed.
02
Drugs
bortezomibdoxorubicin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00116961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116961.